Crewe Advisors’s AnaptysBio ANAB Stock Holding History

Crewe Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-176	Closed	-$4K	–	1030
2022 Q3	$4K	Hold	176	–	–	﹤0.01%	875
2022 Q2	$4K	Buy	+176	New	+$3.9K	﹤0.01%	788

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Crewe Advisors's ANAB Position: Q4 2022 in Review

Crewe Advisors sold out of AnaptysBio (ANAB) in Q4 2022, closing a stake of 176 shares — an estimated $4K sold.

Crewe Advisors first reported a position in ANAB in Q2 2022 and held it in 2 quarters. The position peaked at $4K in Q3 2022. 118 funds tracked by Wall St. Rank hold ANAB as of Q4 2022.

Crewe Advisors reported no remaining AnaptysBio position as of Q4 2022 after selling out during the quarter.
Crewe Advisors sold 176 AnaptysBio shares in Q4 2022, an estimated $4K.
Crewe Advisors first reported a position in AnaptysBio in Q2 2022 and held it in 2 quarters.
Crewe Advisors's AnaptysBio position peaked at $4K in Q3 2022.
118 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2022.

Based on Crewe Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.